Atlas Antibodies has signed an agreement to acquire UK company HistoCyte Laboratories Ltd.
HistoCyte Laboratories’ portfolio of cell line materials provides control of immuno-histochemical assays used in the diagnosis of cancers. These materials have tissue-like properties that enhance the quality of tissue-based assays, states Atlas Antibodies in its press-release. “Formed in 2014, HistoCyte Laboratories has established a significant presence in important markets such as the UK and USA. The company has a strong growth trajectory that is expected to accelerate as acceptance of cell line controls increases rapidly,” the company states.
“We at Atlas Antibodies are delighted to develop this close partnership with the HistoCyte Laboratories team. Atlas Antibodies’ unique proteome-wide portfolio of antibody reagents will, in synergy with HistoCyte Laboratories’ novel cell line controls, provide a powerful set of tools to researchers and clinicians working to understand and diagnose some of the most challenging health issues of our time,” says Atlas Antibodies CEO John Daicic.
Closing is expected during early March 2021.
Photo of John Daicic CEO Atlas Antibodies